9 Meters Biopharma, Inc.

9 Meters Biopharma, Inc. (NASDAQ: NMTR) is a clinical-stage company focused on treating rare or debilitating digestive diseases. Its primary products are vurolenatide, an innovative Phase 2 GLP-1 agonist for short bowel syndrome (SBS), and larazotide, a regulator for non-responsive celiac disease.

Key Highlights

• The company is yet to generate any revenues.
• Its net loss for Q3FY21 (ended September 30, 2021) increased to USD 13.5 million from USD 8.3 million reported in Q3FY20.
• On November 10, 2021, NMTR signed a collaboration agreement with Gustave Roussy, a leading cancer center located in Villejuif, France. Gustave Roussy will use NMTR's small molecule tight junction microbiome modulator NM-102 for preventing gut microbial metabolites and antigens from trafficking into the systemic circulation.
• The stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels, and its RSI Index is at 29.16.
• It is currently trading close to the lower end of its 52-week range of USD 0.70 to USD 2.26.
• NMTR's stock price corrected 40.98% and 48.83% in the past six and nine months, respectively.

Technical Price Chart (as of December 13, 2021). Analysis by Kalkine

Conclusion: Considering the company's loss-making status, lacklustre fundamentals, and other technical indicators, we recommend an "Avoid" rating on the stock at the current price of USD 0.8853, down 2.61%, as of December 13, 2021, at 12:58 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.